Search

Your search keyword '"Niewiadomska, Anna M."' showing total 3 results
Start Over Author "Niewiadomska, Anna M."
3 results on '"Niewiadomska, Anna M."'

1. Defining the risk of SARS-CoV-2 variants on immune protection

Author

DeGrace, Marciela M, Ghedin, Elodie, Frieman, Matthew B, Krammer, Florian, Grifoni, Alba, Alisoltani, Arghavan, Alter, Galit, Amara, Rama R, Baric, Ralph S, Barouch, Dan H, Bloom, Jesse D, Bloyet, Louis-Marie, Bonenfant, Gaston, Boon, Adrianus CM, Boritz, Eli A, Bratt, Debbie L, Bricker, Traci L, Brown, Liliana, Buchser, William J, Carreño, Juan Manuel, Cohen-Lavi, Liel, Darling, Tamarand L, Davis-Gardner, Meredith E, Dearlove, Bethany L, Di, Han, Dittmann, Meike, Doria-Rose, Nicole A, Douek, Daniel C, Drosten, Christian, Edara, Venkata-Viswanadh, Ellebedy, Ali, Fabrizio, Thomas P, Ferrari, Guido, Fischer, Will M, Florence, William C, Fouchier, Ron AM, Franks, John, García-Sastre, Adolfo, Godzik, Adam, Gonzalez-Reiche, Ana Silvia, Gordon, Aubree, Haagmans, Bart L, Halfmann, Peter J, Ho, David D, Holbrook, Michael R, Huang, Yaoxing, James, Sarah L, Jaroszewski, Lukasz, Jeevan, Trushar, Johnson, Robert M, Jones, Terry C, Joshi, Astha, Kawaoka, Yoshihiro, Kercher, Lisa, Koopmans, Marion PG, Korber, Bette, Koren, Eilay, Koup, Richard A, LeGresley, Eric B, Lemieux, Jacob E, Liebeskind, Mariel J, Liu, Zhuoming, Livingston, Brandi, Logue, James P, Luo, Yang, McDermott, Adrian B, McElrath, Margaret J, Meliopoulos, Victoria A, Menachery, Vineet D, Montefiori, David C, Mühlemann, Barbara, Munster, Vincent J, Munt, Jenny E, Nair, Manoj S, Netzl, Antonia, Niewiadomska, Anna M, O’Dell, Sijy, Pekosz, Andrew, Perlman, Stanley, Pontelli, Marjorie C, Rockx, Barry, Rolland, Morgane, Rothlauf, Paul W, Sacharen, Sinai, Scheuermann, Richard H, Schmidt, Stephen D, Schotsaert, Michael, Schultz-Cherry, Stacey, Seder, Robert A, Sedova, Mayya, Sette, Alessandro, Shabman, Reed S, Shen, Xiaoying, Shi, Pei-Yong, Shukla, Maulik, Simon, Viviana, Stumpf, Spencer, Sullivan, Nancy J, Thackray, Larissa B, and Theiler, James

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Biological Sciences, Emerging Infectious Diseases, Pneumonia, Vaccine Related, Pneumonia & Influenza, Infectious Diseases, Biodefense, Immunization, Biotechnology, Prevention, Lung, Prevention of disease and conditions, and promotion of well-being, 2.1 Biological and endogenous factors, 3.4 Vaccines, Aetiology, Infection, Good Health and Well Being, Animals, Biological Evolution, COVID-19, COVID-19 Vaccines, Humans, National Institute of Allergy and Infectious Diseases (U.S.), Pandemics, Pharmacogenomic Variants, SARS-CoV-2, United States, Virulence, General Science & Technology
Abstract

The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or vaccination. To address the public health threat caused by the increasing SARS-CoV-2 genomic diversity, the National Institute of Allergy and Infectious Diseases within the National Institutes of Health established the SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme. This effort was designed to provide a real-time risk assessment of SARS-CoV-2 variants that could potentially affect the transmission, virulence, and resistance to infection- and vaccine-induced immunity. The SAVE programme is a critical data-generating component of the US Government SARS-CoV-2 Interagency Group to assess implications of SARS-CoV-2 variants on diagnostics, vaccines and therapeutics, and for communicating public health risk. Here we describe the coordinated approach used to identify and curate data about emerging variants, their impact on immunity and effects on vaccine protection using animal models. We report the development of reagents, methodologies, models and notable findings facilitated by this collaborative approach and identify future challenges. This programme is a template for the response to rapidly evolving pathogens with pandemic potential by monitoring viral evolution in the human population to identify variants that could reduce the effectiveness of countermeasures.

Published
2022

2. US National Institutes of Health Prioritization of SARS-CoV-2 Variants

Author

Turner, Sam, Alisoltani, Arghavan, Bratt, Debbie, Cohen-Lavi, Liel, Dearlove, Bethany L., Drosten, Christian, Fischer, Will M., Fouchier, Ron A.M., Gonzalez-Reiche, Ana Silvia, Jaroszewski, Lukasz, Khalil, Zain, LeGresley, Eric, Johnson, Marc, Jones, Terry C., Muhlemann, Barbara, O'Connor, David, Sedova, Mayya, Shukla, Maulik, Theiler, James, Wallace, Zachary S., Yoon, Hyejin, Zhang, Yun, van Bakel, Harm, Degrace, Marciela M., Ghedin, Elodie, Godzik, Adam, Hertz, Tomer, Korber, Bette, Lemieux, Jacob, Niewiadomska, Anna M., Post, Diane J., Rolland, Morgane, Scheuermann, Richard, and Smith, Derek J.

Subjects
Values -- Analysis, Microbial mutation -- Health aspects, Epidemiology -- Methods, Health
Abstract

As part of the US National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) SARS-CoV-2 Assessment of Viral Evolution (SAVE) effort to combat the SARS-CoV-2 pandemic, [...]

Published
2023
Full Text
View/download PDF

3. Defining the risk of SARS-CoV-2 variants on immune protection

Author

DeGrace, Marciela M., Ghedin, Elodie, Frieman, Matthew B., Krammer, Florian, Grifoni, Alba, Alisoltani, Arghavan, Alter, Galit, Amara, Rama R., Baric, Ralph S., Barouch, Dan H., Bloom, Jesse D., Bloyet, Louis Marie, Bonenfant, Gaston, Boon, Adrianus C.M., Boritz, Eli A., Bratt, Debbie L., Bricker, Traci L., Brown, Liliana, Buchser, William J., Carreño, Juan Manuel, Cohen-Lavi, Liel, Darling, Tamarand L., Davis-Gardner, Meredith E., Dearlove, Bethany L., Di, Han, Dittmann, Meike, Doria-Rose, Nicole A., Douek, Daniel C., Drosten, Christian, Edara, Venkata Viswanadh, Ellebedy, Ali, Fabrizio, Thomas P., Ferrari, Guido, Fischer, Will M., Florence, William C., Fouchier, Ron A.M., Franks, John, García-Sastre, Adolfo, Godzik, Adam, Gonzalez-Reiche, Ana Silvia, Gordon, Aubree, Haagmans, Bart L., Halfmann, Peter J., Ho, David D., Holbrook, Michael R., Huang, Yaoxing, James, Sarah L., Jaroszewski, Lukasz, Jeevan, Trushar, Johnson, Robert M., Jones, Terry C., Joshi, Astha, Kawaoka, Yoshihiro, Kercher, Lisa, Koopmans, Marion P.G., Korber, Bette, Koren, Eilay, Koup, Richard A., LeGresley, Eric B., Lemieux, Jacob E., Liebeskind, Mariel J., Liu, Zhuoming, Livingston, Brandi, Logue, James P., Luo, Yang, McDermott, Adrian B., McElrath, Margaret J., Meliopoulos, Victoria A., Menachery, Vineet D., Montefiori, David C., Mühlemann, Barbara, Munster, Vincent J., Munt, Jenny E., Nair, Manoj S., Netzl, Antonia, Niewiadomska, Anna M., O’Dell, Sijy, Pekosz, Andrew, Perlman, Stanley, Pontelli, Marjorie C., Rockx, Barry, Rolland, Morgane, Rothlauf, Paul W., Sacharen, Sinai, Scheuermann, Richard H., Schmidt, Stephen D., Schotsaert, Michael, Schultz-Cherry, Stacey, Seder, Robert A., Sedova, Mayya, Sette, Alessandro, Shabman, Reed S., Shen, Xiaoying, Shi, Pei Yong, Shukla, Maulik, Simon, Viviana, Stumpf, Spencer, Sullivan, Nancy J., Thackray, Larissa B., Theiler, James, Thomas, Paul G., Trifkovic, Sanja, Türeli, Sina, Turner, Samuel A., Vakaki, Maria A., van Bakel, Harm, VanBlargan, Laura A., Vincent, Leah R., Wallace, Zachary S., Wang, Li, Wang, Maple, Wang, Pengfei, Wang, Wei, Weaver, Scott C., Webby, Richard J., Weiss, Carol D., Wentworth, David E., Weston, Stuart M., Whelan, Sean P.J., Whitener, Bradley M., Wilks, Samuel H., Xie, Xuping, Ying, Baoling, Yoon, Hyejin, Zhou, Bin, Hertz, Tomer, Smith, Derek J., Diamond, Michael S., Post, Diane J., Suthar, Mehul S., DeGrace, Marciela M., Ghedin, Elodie, Frieman, Matthew B., Krammer, Florian, Grifoni, Alba, Alisoltani, Arghavan, Alter, Galit, Amara, Rama R., Baric, Ralph S., Barouch, Dan H., Bloom, Jesse D., Bloyet, Louis Marie, Bonenfant, Gaston, Boon, Adrianus C.M., Boritz, Eli A., Bratt, Debbie L., Bricker, Traci L., Brown, Liliana, Buchser, William J., Carreño, Juan Manuel, Cohen-Lavi, Liel, Darling, Tamarand L., Davis-Gardner, Meredith E., Dearlove, Bethany L., Di, Han, Dittmann, Meike, Doria-Rose, Nicole A., Douek, Daniel C., Drosten, Christian, Edara, Venkata Viswanadh, Ellebedy, Ali, Fabrizio, Thomas P., Ferrari, Guido, Fischer, Will M., Florence, William C., Fouchier, Ron A.M., Franks, John, García-Sastre, Adolfo, Godzik, Adam, Gonzalez-Reiche, Ana Silvia, Gordon, Aubree, Haagmans, Bart L., Halfmann, Peter J., Ho, David D., Holbrook, Michael R., Huang, Yaoxing, James, Sarah L., Jaroszewski, Lukasz, Jeevan, Trushar, Johnson, Robert M., Jones, Terry C., Joshi, Astha, Kawaoka, Yoshihiro, Kercher, Lisa, Koopmans, Marion P.G., Korber, Bette, Koren, Eilay, Koup, Richard A., LeGresley, Eric B., Lemieux, Jacob E., Liebeskind, Mariel J., Liu, Zhuoming, Livingston, Brandi, Logue, James P., Luo, Yang, McDermott, Adrian B., McElrath, Margaret J., Meliopoulos, Victoria A., Menachery, Vineet D., Montefiori, David C., Mühlemann, Barbara, Munster, Vincent J., Munt, Jenny E., Nair, Manoj S., Netzl, Antonia, Niewiadomska, Anna M., O’Dell, Sijy, Pekosz, Andrew, Perlman, Stanley, Pontelli, Marjorie C., Rockx, Barry, Rolland, Morgane, Rothlauf, Paul W., Sacharen, Sinai, Scheuermann, Richard H., Schmidt, Stephen D., Schotsaert, Michael, Schultz-Cherry, Stacey, Seder, Robert A., Sedova, Mayya, Sette, Alessandro, Shabman, Reed S., Shen, Xiaoying, Shi, Pei Yong, Shukla, Maulik, Simon, Viviana, Stumpf, Spencer, Sullivan, Nancy J., Thackray, Larissa B., Theiler, James, Thomas, Paul G., Trifkovic, Sanja, Türeli, Sina, Turner, Samuel A., Vakaki, Maria A., van Bakel, Harm, VanBlargan, Laura A., Vincent, Leah R., Wallace, Zachary S., Wang, Li, Wang, Maple, Wang, Pengfei, Wang, Wei, Weaver, Scott C., Webby, Richard J., Weiss, Carol D., Wentworth, David E., Weston, Stuart M., Whelan, Sean P.J., Whitener, Bradley M., Wilks, Samuel H., Xie, Xuping, Ying, Baoling, Yoon, Hyejin, Zhou, Bin, Hertz, Tomer, Smith, Derek J., Diamond, Michael S., Post, Diane J., and Suthar, Mehul S.

Abstract

The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or vaccination. To address the public health threat caused by the increasing SARS-CoV-2 genomic diversity, the National Institute of Allergy and Infectious Diseases within the National Institutes of Health established the SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme. This effort was designed to provide a real-time risk assessment of SARS-CoV-2 variants that could potentially affect the transmission, virulence, and resistance to infection- and vaccine-induced immunity. The SAVE programme is a critical data-generating component of the US Government SARS-CoV-2 Interagency Group to assess implications of SARS-CoV-2 variants on diagnostics, vaccines and therapeutics, and for communicating public health risk. Here we describe the coordinated approach used to identify and curate data about emerging variants, their impact on immunity and effects on vaccine protection using animal models. We report the development of reagents, methodologies, models and notable findings facilitated by this collaborative approach and identify future challenges. This programme is a template for the response to rapidly evolving pathogens with pandemic potential by monitoring viral evolution in the human population to identify variants that could reduce the effectiveness of countermeasures.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results